CX11 tablets: testing safe doses for obesity and weight-related conditions
Official title: A Phase 1b Study Investigating Safety, Pharmacokinetics, and Pharmacodynamics of CX11 Tablets in Participants With Obesity or Overweight With Weight-Related Comorbidities
Run by Corxel Pharmaceuticals · NCT07652047 · Data updated 2026-11-12
This study tests different doses of CX11 tablets to see if they are safe and tolerable in adults with obesity or overweight and related health issues.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 55 Years |
| Sex | Women only |
| Enrollment | 90 (estimated) |
| Sponsor | Corxel Pharmaceuticals Industry-sponsored |
| Locations | 2 sites (Las Vegas, Nevada and 1 other locations) |
| Status | Recruiting |
| Started | May 11, 2026 |
| Main results expected | March 2027 |
| Study ends | June 2027 |
| Registry record updated | June 17, 2026 |
| Trial ID | NCT07652047 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18-55 with BMI 30.0–39.9, or 27.0–29.9 with at least one weight-related comorbidity (prediabetes, hypertension, dyslipidemia, or OSA), and a recent history of weight-loss attempts.
✕Probably not a fit
Individuals with diabetes, obesity due to endocrine/genetic causes, recent use of weight-loss drugs or obesity surgeries, or other medical risks may not benefit from this trial.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a multi-center, randomized, placebo-controlled, double-blind (within cohorts) Phase 1b trial designed to assess safety, how the drug behaves in the body (pharmacokinetics), and how it affects the body (pharmacodynamics) in adults with obesity or overweight and at least one weight-related comorbidity. Participants will receive CX11 at varying doses or placebo across cohorts, with sponsor unblinding allowances as needed. The study excludes individuals with certain medical conditions or recent weight-loss interventions to ensure clear safety and PK/PD signals. The primary aim is to identify safe dose ranges and characterize tolerability, with secondary observations on biological effects relevant to weight management.
Why it matters
Potential benefit: If successful, CX11 could establish a safe dosing range and provide preliminary signals on weight-related biological effects.
How similar studies have gone: Phase 1b trials of similar weight-management approaches have shown safety signals, but the specific CX11 program is novel in its exact formulation and dosing.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female, 18-55 years. * BMI ≥30.0 to ≤39.9 kg/m², or ≥27.0 to \<30.0 kg/m² with at least 1 weight-related comorbidity: prediabetes, hypertension, dyslipidemia, or obstructive sleep apnea. * Prior unsuccessful diet/exercise weight-loss attempt and stable body weight within 90 days. * Able to comply with study procedures and reproductive requirements. Exclusion Criteria: * Diabetes or obesity due to endocrine/genetic causes. * Recent weight-loss drugs, GLP-1-based therapy, glucose-lowering drugs, obesity surgery/device, or investigational treatment. * Significant cardiovascular, ECG/QT, pancreatic, gallbladder, GI, liver, kidney, thyroid, psychiatric, malignant, infectious, autoimmune, or lab abnormality risks. * Personal/family history of medullary thyroid carcinoma or multiple endocrine neoplasia. * Pregnancy, breastfeeding, recent nicotine/drug use, excessive alcohol use, or any condition/medication making participation inappropriate.
Where it's running
-
Corxel Investigational site
Las Vegas, Nevada, United States Recruiting -
Corxel Investigational Site
Austin, Texas, United States Recruiting
Study contacts
- Study coordinator: Study coordinator
- Email: information.center@corxelbio.com
- Phone: 201-268-3723
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
How incretin treatments affect muscle mass and function in people with overweight or obesity
This study will see how drugs like semaglutide and tirzepatide influence fat-free mass, muscle strength, and physical function in adults with overweight or obesity.
-
Dose find for remimazolam plus alfentanil for gastroscopy in obese adults
This trial tests what dose of remimazolam besylate with alfentanil best sedates obese adults during gastroscopy.
-
Two-Year Weight Loss With GLP-1 Medications Compared With Sleeve Gastrectomy in Adults
This study compares how much weight adults lose over two years when starting GLP-1 medicines versus adults who had sleeve gastrectomy at the same center.
-
Gut barrier and inflammation after fast-food overfeeding in adults
This study tests whether 14 days of fast-food overfeeding can alter gut barrier function and trigger inflammation in adults who are generally healthy.
-
High BMI and periodontitis in Thai adults under 60
This study tests how common high BMI and periodontitis are among Thai adults aged 18–59 and what factors are linked to them.
-
GLP-1 weight‑loss medicine: finding who will benefit most
This study tests whether a GLP-1 drug called semaglutide helps with weight loss by changing eating behavior, to see which people it helps the most.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.